Cargando...
Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis
BACKGROUND: Budesonide multimatrix (MMX) system has been approved for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), and offers potential safety benefits over more commonly utilized corticosteroid therapies. OBJECTIVES: In a real-world setting we aimed...
Gardado en:
| Publicado en: | Inflamm Intest Dis |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
S. Karger AG
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6751477/ https://ncbi.nlm.nih.gov/pubmed/31559263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000501004 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|